Amundi
REGN icon

Amundi’s Regeneron Pharmaceuticals REGN Stock Holding History

Amundi’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$780M Buy
1,009,798
+217,892
+28% +$167M 0.21% 85
2025
Q4 		$611M Buy
791,906
+170,165
+27% +$116M 0.17% 127
2025
Q3 		$364M Sell
621,741
-275,390
-31% -$156M 0.12% 154
2025
Q2 		$491M Sell
897,131
-706,770
-44% -$394M 0.17% 117
2025
Q1 		$980M Buy
1,603,901
+52,166
+3% +$35.9M 0.36% 55
2024
Q4 		$1.14B Buy
1,551,735
+487,489
+46% +$409M 0.4% 50
2024
Q3 		$1.07B Sell
1,064,246
-72
-0% -$80.1K 0.39% 53
2024
Q2 		$1.09B Buy
1,064,318
+7,859
+0.7% +$7.62M 0.42% 50
2024
Q1 		$945M Buy
1,056,459
+142,334
+16% +$135M 0.41% 50
2023
Q4 		$825M Buy
914,125
+228,839
+33% +$188M 0.37% 56
2023
Q3 		$575M Buy
685,286
+574
+0.1% +$451K 0.28% 81
2023
Q2 		$492M Sell
684,712
-87,503
-11% -$67.5M 0.25% 99
2023
Q1 		$637M Buy
772,215
+76,780
+11% +$57.9M 0.34% 62
2022
Q4 		$494M Buy
695,435
+40,245
+6% +$29.7M 0.27% 96
2022
Q3 		$489M Buy
655,190
+100,682
+18% +$63.4M 0.29% 83
2022
Q2 		$332M Buy
554,508
+55,578
+11% +$36.1M 0.27% 96
2022
Q1 		$360M Buy
498,930
+38,600
+8% +$24.4M 0.24% 105
2021
Q4 		$284M Buy
460,330
+33,873
+8% +$20.8M 0.18% 137
2021
Q3 		$258M Buy
426,457
+225,038
+112% +$140M 0.18% 137
2021
Q2 		$113M Buy
+201,419
New +$102M 0.08% 266

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Amundi's REGN Position: Q1 2026 in Review

Amundi increased its Regeneron Pharmaceuticals (REGN) stake by 28% in Q1 2026, buying an estimated $167M and bringing the position to 1,009,798 shares worth $780M. The position accounts for 0.21% of the portfolio, ranked #85.

Amundi first reported a position in REGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.14B in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Amundi held 1,009,798 shares of Regeneron Pharmaceuticals worth $780M as of Q1 2026.
  • Amundi bought 217,892 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $167M.
  • Regeneron Pharmaceuticals made up 0.21% of Amundi's portfolio in Q1 2026, its #85 holding.
  • Amundi first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Amundi's Regeneron Pharmaceuticals position peaked at $1.14B in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.